Developer docs
API playgroundTry for free, no card

Search company profiles

Dimerix Biosciences

Full company profile

uuid00066be

Namestring
Dimerix Biosciences
Legal namestring
Dimerix Limited
Websiteurl
dimerix.com
Company typeenum
Public
Founded yearint
2004
Descriptiontext

Dimerix Limited (ASX:DXB) is a clinical-stage biopharmaceutical company headquartered in Fitzroy, Melbourne, Australia, developing therapeutics for inflammatory diseases with high unmet need. Its lead candidate, DMX-200 (repagermanium), is an oral chemokine receptor CCR2 blocker administered as an adjunct to standard angiotensin receptor blocker (ARB) therapy. DMX-200 is currently in the Phase 3 ACTION3 trial for Focal Segmental Glomerulosclerosis (FSGS), a rare progressive kidney disease affecting at least 210,000 people globally with no approved disease-modifying treatment. DMX-200 has received Orphan Drug Designation from both the FDA and EMA, with composition-of-matter patents extending to 2032 (potentially to 2042). The Phase 2a study showed 86% of patients achieving reduced proteinuria versus placebo and 29% achieving a greater than 40% reduction when added to background ARB therapy.

The company's discovery engine is Receptor-HIT (Heteromer Investigation Technology), a patented cell-based assay platform that identifies pairs of receptors (heteromers) with novel pharmacological behavior when ligands bind, applied to G-protein coupled receptor (GPCR) targets. The platform has yielded a second pre-clinical candidate, DMX-700, targeting orphan respiratory/renal disease. Receptor-HIT is also available for out-licensing to third parties.

Dimerix operates a capital-light, partner-led business model. It retains clinical development and IP responsibilities and out-licenses regional commercialization rights to partners that bear commercial risk. Current partners include Amicus Therapeutics (US, up to USD 560M in milestones plus royalties), Advanz Pharma (Europe, Canada, Australia, New Zealand), FUSO Pharmaceutical (Japan, ¥300M upfront), and Everest Medicines (Greater China, South Korea, Singapore, Malaysia, Thailand, Indonesia, Vietnam, Philippines). Revenue today consists of upfront payments, development and regulatory milestones, and future royalties; the company is pre-commercial with last patient last dose in the Phase 3 ACTION3 trial expected in March 2028.

Short descriptiontext

Dimerix Biosciences (ASX:DXB) is a Melbourne-based clinical-stage biopharmaceutical company developing DMX-200, a CCR2 blocker in Phase 3 trials for the rare kidney disease FSGS, using its proprietary Receptor-HIT heteromer discovery platform and a global partner-led out-licensing model.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMelbourne, Australia
HQ citystring
Melbourne
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biopharmaceuticals, rare kidney disease therapeutics, drug discovery platform, orphan drug development, inflammatory disease treatments
Industry2 codes
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-Stage Biopharmaceuticals (Rare Kidney Disease)
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Licensing and milestone payments
TypeLicensing Royalties
Description

Dimerix generates revenue through upfront payments, development milestones, regulatory milestones, and sales royalties from regional licensing partners commercialising DMX-200 in their respective territories. Partners bear all commercial risk and costs in their regions.

ainvest.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Dimerix Biosciences is a clinical-stage biopharmaceutical company developing drug candidates for inflammatory diseases, with its lead product DMX-200 (a CCR2 chemokine receptor blocker) in Phase 3 trials for Focal Segmental Glomerulosclerosis (FSGS) and a second candidate DMX-700 in pre-clinical development for orphan respiratory/renal disease. The company leverages its proprietary Receptor-HIT cell-based assay platform to identify heteromer receptor interactions and discover differentiated drugs targeting GPCRs, and operates a global out-licensing model where regional pharmaceutical partners commercialize DMX-200 in their territories.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 86% of patients demonstrated reduced proteinuria on DMX-200 versus placebo; 29% achieved >40% reduction in proteinuria in addition to background ARB therapy
+2 more records
Product overview1 text field

Dimerix is a clinical-stage biopharmaceutical company with a portfolio of drug candidates for inflammatory diseases, including kidney and respiratory diseases. The company's lead product is DMX-200 (Phase 3, for Focal Segmental Glomerulosclerosis), with a second product candidate DMX-700 in pre-clinical development for orphan respiratory/renal disease. Dimerix operates its proprietary Receptor-HIT technology platform for drug discovery, which is available for global licensing. The company pursues a partnering strategy, having licensed DMX-200 rights to multiple global partners including Amicus Therapeutics (US), Advanz Pharma (Europe/Canada/Australia/NZ), FUSO Pharmaceutical (Japan), and Everest Medicines (Asia).

Product and service3 records
1DMX-200 (repagermanium)
CategoryClinical-stage drug candidate (kidney disease)
Description

Chemokine receptor (CCR2) blocker administered as adjunct to standard angiotensin II type I receptor blocker (ARB) therapy. Currently in Phase 3 (ACTION3) clinical trials for Focal Segmental Glomerulosclerosis (FSGS), a rare progressive kidney disease.

2DMX-700
CategoryPre-clinical drug candidate (respiratory/renal disease)
Description

Pre-clinical drug candidate targeting orphan respiratory and renal diseases, designed to address unmet medical needs in inflammatory diseases affecting the respiratory and renal systems. Developed using the proprietary Receptor-HIT platform.

3Receptor-HIT Technology Platform
CategoryDrug discovery technology platform (licensable)
Description

Proprietary patented cell-based assay platform that identifies pairs of different receptors (heteromers) that function jointly when ligands bind. Applied to G-protein coupled receptors (GPCRs) for drug discovery across target validation, compound profiling, and candidate optimisation. Available for global licensing to third-party developers.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-16
Description

Exclusive licensing agreement for DMX-200 covering Greater China, South Korea, and Southeast Asian countries (Singapore, Malaysia, Thailand, Indonesia, Vietnam, Philippines). Everest assumes commercial risk and responsibilities for development and commercialization in these territories. Dimerix retains clinical development and IP responsibilities. Dimerix shares surged 21.2% to A$0.20 following the announcement.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Secured exclusive US rights for DMX-200 with potential deal value of up to USD 560 million in milestones and royalties. Amicus bears commercial risk in the US territory while Dimerix retains clinical development and IP responsibilities.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Acquired exclusive rights for DMX-200 in Europe, Canada, Australia, and New Zealand. Advanz assumes commercialization responsibilities and commercial risk in these territories.

4FUSO Pharmaceutical
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Obtained Japan rights for DMX-200 with ¥300 million upfront payment. FUSO handles commercialization in Japan, reflecting the different market dynamics with lower upfront payments compared to the US.

ainvest.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Travere Therapeutics is the most directly comparable peer, developing sparsentan (FILSPARI) for FSGS and IgA nephropathy — the same rare kidney disease space as DMX-200. Both companies are running late-stage trials targeting proteinuria reduction in FSGS with potential first-in-class positioning.

TypeDirect peer
Description

Chinook Therapeutics (acquired by Novartis in 2023) developed atrasentan and other precision medicines for rare kidney diseases including IgA nephropathy. Directly comparable as a clinical-to-commercial rare kidney disease biotech with similar partnership-driven development model.

TypeDirect peer
Description

Calliditas developed Nefecon (Tarpeyo), the first FDA-approved drug for IgA nephropathy, addressing proteinuria and kidney function decline in rare glomerular diseases. Highly comparable as a small-cap European/Australian-adjacent biotech that took a rare kidney disease therapy through Phase 3 and to approval via partnering.

TypeEmerging player
Description

Vera Therapeutics is developing atacicept for IgA nephropathy and other autoimmune kidney diseases, with Phase 3 data in a directly adjacent rare nephrology indication. Comparable as a clinical-stage rare kidney disease biotech with similar value-driving thesis around proteinuria reduction.

5ChemoCentryx
TypeDirect peer
Description

ChemoCentryx (acquired by Amgen in 2022) developed tavneos, an oral complement inhibitor for ANCA-associated vasculitis, and was a pioneer in chemokine receptor (CCR1/CCR2/CCR5) drug discovery. Highly comparable to Dimerix for its focus on chemokine receptor pharmacology and small-molecule rare-disease therapeutics.

TypeBroad incumbent
Description

Otsuka is a major incumbent in rare kidney disease through tolvaptan (Jynarque) for ADPKD and broader nephrology pipeline. Comparable as a large pharmaceutical player operating in the same orphan kidney disease space, providing both competitive context and a precedent for partner-led commercialization of rare renal therapies.

TypeBroad incumbent
Description

Alexion (now part of AstraZeneca) is the dominant commercial player in rare disease therapeutics including nephrology-adjacent indications. Comparable as a large established rare-disease commercial organization and potential strategic acquirer/licensee for orphan renal assets like DMX-200.

8Goldfinch Bio
TypeEmerging player
Description

Goldfinch Bio was a clinical-stage biotech focused on precision medicines for kidney diseases including FSGS, with a GPCR-adjacent mechanism focus. Comparable as an emerging rare kidney disease player pursuing similar proteinuria endpoints, though now largely inactive.

TypeOthers
Description

Amicus is not a direct competitor but a licensee of DMX-200 for the US (up to $560M in milestones) and is also developing Galafold and other rare-disease therapies. Relevant as Dimerix's commercial partner and a bellwether for how the US FSGS market will be approached post-approval.

TypeDirect peer
Description

BridgeBio's affiliate companies developed infigratinib (and other rare disease programs) and acquired an FSGS program through its BridgeBio Pharma affiliate. Comparable as a clinical-to-commercial rare disease company with deep orphan drug expertise and a similar partnering-centric business model.

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Dimerix Biosciences

Clinical-Stage Biopharmaceuticals (Rare Kidney Disease)dimerix.com

Dimerix Biosciences (ASX:DXB) is a Melbourne-based clinical-stage biopharmaceutical company developing DMX-200, a CCR2 blocker in Phase 3 trials for the rare kidney disease FSGS, using its proprietary Receptor-HIT heteromer discovery platform and a global partner-led out-licensing model.

What Dimerix Biosciences does

Dimerix Limited (ASX:DXB) is a clinical-stage biopharmaceutical company headquartered in Fitzroy, Melbourne, Australia, developing therapeutics for inflammatory diseases with high unmet need. Its lead candidate, DMX-200 (repagermanium), is an oral chemokine receptor CCR2 blocker administered as an adjunct to standard angiotensin receptor blocker (ARB) therapy. DMX-200 is currently in the Phase 3 ACTION3 trial for Focal Segmental Glomerulosclerosis (FSGS), a rare progressive kidney disease affecting at least 210,000 people globally with no approved disease-modifying treatment. DMX-200 has received Orphan Drug Designation from both the FDA and EMA, with composition-of-matter patents extending to 2032 (potentially to 2042). The Phase 2a study showed 86% of patients achieving reduced proteinuria versus placebo and 29% achieving a greater than 40% reduction when added to background ARB therapy.

The company's discovery engine is Receptor-HIT (Heteromer Investigation Technology), a patented cell-based assay platform that identifies pairs of receptors (heteromers) with novel pharmacological behavior when ligands bind, applied to G-protein coupled receptor (GPCR) targets. The platform has yielded a second pre-clinical candidate, DMX-700, targeting orphan respiratory/renal disease. Receptor-HIT is also available for out-licensing to third parties.

Dimerix operates a capital-light, partner-led business model. It retains clinical development and IP responsibilities and out-licenses regional commercialization rights to partners that bear commercial risk. Current partners include Amicus Therapeutics (US, up to USD 560M in milestones plus royalties), Advanz Pharma (Europe, Canada, Australia, New Zealand), FUSO Pharmaceutical (Japan, ¥300M upfront), and Everest Medicines (Greater China, South Korea, Singapore, Malaysia, Thailand, Indonesia, Vietnam, Philippines). Revenue today consists of upfront payments, development and regulatory milestones, and future royalties; the company is pre-commercial with last patient last dose in the Phase 3 ACTION3 trial expected in March 2028.

Dimerix Biosciences firmographics

Firmographics
Name
Dimerix Biosciences
Legal name
Dimerix Limited
Website
https://dimerix.com
Company type
Public
Founded year
2004
Operating status
Operating
Headcount range
11–50 employees
Short description
Dimerix Biosciences (ASX:DXB) is a Melbourne-based clinical-stage biopharmaceutical company developing DMX-200, a CCR2 blocker in Phase 3 trials for the rare kidney disease FSGS, using its proprietary Receptor-HIT heteromer discovery platform and a global partner-led out-licensing model.
Ownership category
akta.pro rank

Dimerix Biosciences industry classification

Industry
Product category
Clinical-Stage Biopharmaceuticals (Rare Kidney Disease)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Clinical-stage biopharmaceuticals
  • Rare kidney disease therapeutics
  • Drug discovery platform
  • Orphan drug development
  • Inflammatory disease treatments

Where Dimerix Biosciences is headquartered

Location

Headquarters

HQ city
Melbourne
HQ country
Australia
HQ region
Oceania

Offices1 record

Markets served

Dimerix Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Licensing and milestone payments: Dimerix generates revenue through upfront payments, development milestones, regulatory milestones, and sales royalties from regional licensing partners commercialising DMX-200 in their respective territories. Partners bear all commercial risk and costs in their regions.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Dimerix Biosciences product offering

Product offering

Core offering

Dimerix Biosciences is a clinical-stage biopharmaceutical company developing drug candidates for inflammatory diseases, with its lead product DMX-200 (a CCR2 chemokine receptor blocker) in Phase 3 trials for Focal Segmental Glomerulosclerosis (FSGS) and a second candidate DMX-700 in pre-clinical development for orphan respiratory/renal disease. The company leverages its proprietary Receptor-HIT cell-based assay platform to identify heteromer receptor interactions and discover differentiated drugs targeting GPCRs, and operates a global out-licensing model where regional pharmaceutical partners commercialize DMX-200 in their territories.

Product overview

Dimerix is a clinical-stage biopharmaceutical company with a portfolio of drug candidates for inflammatory diseases, including kidney and respiratory diseases. The company's lead product is DMX-200 (Phase 3, for Focal Segmental Glomerulosclerosis), with a second product candidate DMX-700 in pre-clinical development for orphan respiratory/renal disease. Dimerix operates its proprietary Receptor-HIT technology platform for drug discovery, which is available for global licensing. The company pursues a partnering strategy, having licensed DMX-200 rights to multiple global partners including Amicus Therapeutics (US), Advanz Pharma (Europe/Canada/Australia/NZ), FUSO Pharmaceutical (Japan), and Everest Medicines (Asia).

Differentiator

Problem solved

Functional benefit

Products and services

  • DMX-200 (repagermanium) Chemokine receptor (CCR2) blocker administered as adjunct to standard angiotensin II type I receptor blocker (ARB) therapy. Currently in Phase 3 (ACTION3) clinical trials for Focal Segmental Glomerulosclerosis (FSGS), a rare progressive kidney disease.
  • DMX-700 Pre-clinical drug candidate targeting orphan respiratory and renal diseases, designed to address unmet medical needs in inflammatory diseases affecting the respiratory and renal systems. Developed using the proprietary Receptor-HIT platform.
  • Receptor-HIT Technology Platform Proprietary patented cell-based assay platform that identifies pairs of different receptors (heteromers) that function jointly when ligands bind. Applied to G-protein coupled receptors (GPCRs) for drug discovery across target validation, compound profiling, and candidate optimisation. Available for global licensing to third-party developers.

Quantifiable outcome

  • 86% of patients demonstrated reduced proteinuria on DMX-200 versus placebo; 29% achieved >40% reduction in proteinuria in addition to background ARB therapy
  • +2 more outcomes

Companies that use Dimerix Biosciences

Customer profile

Segments1 record

Ideal customer profiles2 records

Dimerix Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Dimerix Biosciences partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Everest MedicinescoreChannel Partner/ Reseller/ Distributor · 16 June 2026Exclusive licensing agreement for DMX-200 covering Greater China, South Korea, and Southeast Asian countries (Singapore, Malaysia, Thailand, Indonesia, Vietnam, Philippines). Everest assumes commercial risk and responsibilities for development and commercialization in these territories. Dimerix retains clinical development and IP responsibilities. Dimerix shares surged 21.2% to A$0.20 following the announcement.
  • Amicus TherapeuticscoreChannel Partner/ Reseller/ DistributorSecured exclusive US rights for DMX-200 with potential deal value of up to USD 560 million in milestones and royalties. Amicus bears commercial risk in the US territory while Dimerix retains clinical development and IP responsibilities.
  • Advanz PharmacoreChannel Partner/ Reseller/ DistributorAcquired exclusive rights for DMX-200 in Europe, Canada, Australia, and New Zealand. Advanz assumes commercialization responsibilities and commercial risk in these territories.
  • FUSO PharmaceuticalcoreChannel Partner/ Reseller/ DistributorObtained Japan rights for DMX-200 with ¥300 million upfront payment. FUSO handles commercialization in Japan, reflecting the different market dynamics with lower upfront payments compared to the US.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Dimerix Biosciences competitors and assessment

Company assessment

Direct peers

  • Travere Therapeutics: Travere Therapeutics is the most directly comparable peer, developing sparsentan (FILSPARI) for FSGS and IgA nephropathy — the same rare kidney disease space as DMX-200. Both companies are running late-stage trials targeting proteinuria reduction in FSGS with potential first-in-class positioning.
  • Chinook Therapeutics: Chinook Therapeutics (acquired by Novartis in 2023) developed atrasentan and other precision medicines for rare kidney diseases including IgA nephropathy. Directly comparable as a clinical-to-commercial rare kidney disease biotech with similar partnership-driven development model.
  • Calliditas Therapeutics: Calliditas developed Nefecon (Tarpeyo), the first FDA-approved drug for IgA nephropathy, addressing proteinuria and kidney function decline in rare glomerular diseases. Highly comparable as a small-cap European/Australian-adjacent biotech that took a rare kidney disease therapy through Phase 3 and to approval via partnering.
  • ChemoCentryx: ChemoCentryx (acquired by Amgen in 2022) developed tavneos, an oral complement inhibitor for ANCA-associated vasculitis, and was a pioneer in chemokine receptor (CCR1/CCR2/CCR5) drug discovery. Highly comparable to Dimerix for its focus on chemokine receptor pharmacology and small-molecule rare-disease therapeutics.
  • BridgeBio Pharma: BridgeBio's affiliate companies developed infigratinib (and other rare disease programs) and acquired an FSGS program through its BridgeBio Pharma affiliate. Comparable as a clinical-to-commercial rare disease company with deep orphan drug expertise and a similar partnering-centric business model.

Emerging players

  • Vera Therapeutics: Vera Therapeutics is developing atacicept for IgA nephropathy and other autoimmune kidney diseases, with Phase 3 data in a directly adjacent rare nephrology indication. Comparable as a clinical-stage rare kidney disease biotech with similar value-driving thesis around proteinuria reduction.
  • Goldfinch Bio: Goldfinch Bio was a clinical-stage biotech focused on precision medicines for kidney diseases including FSGS, with a GPCR-adjacent mechanism focus. Comparable as an emerging rare kidney disease player pursuing similar proteinuria endpoints, though now largely inactive.

Broad incumbents

  • Otsuka Pharmaceutical: Otsuka is a major incumbent in rare kidney disease through tolvaptan (Jynarque) for ADPKD and broader nephrology pipeline. Comparable as a large pharmaceutical player operating in the same orphan kidney disease space, providing both competitive context and a precedent for partner-led commercialization of rare renal therapies.
  • Alexion / AstraZeneca Rare Disease: Alexion (now part of AstraZeneca) is the dominant commercial player in rare disease therapeutics including nephrology-adjacent indications. Comparable as a large established rare-disease commercial organization and potential strategic acquirer/licensee for orphan renal assets like DMX-200.

Others

  • Amicus Therapeutics: Amicus is not a direct competitor but a licensee of DMX-200 for the US (up to $560M in milestones) and is also developing Galafold and other rare-disease therapies. Relevant as Dimerix's commercial partner and a bellwether for how the US FSGS market will be approached post-approval.

Market position

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights6 records

Customer concentration

Dimerix Biosciences social profiles

Digital presence

Dimerix Biosciences compliance and trust

Trust signal

Compliance2 records

Dimerix Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Dimerix Biosciences leadership team

Management profile

Number of profiles

Profiles8 records

Dimerix Biosciences subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Dimerix Biosciences funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Dimerix Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dimerix Biosciences

What does Dimerix Biosciences do?

Dimerix Biosciences is a clinical-stage biopharmaceutical company developing drug candidates for inflammatory diseases, with its lead product DMX-200 (a CCR2 chemokine receptor blocker) in Phase 3 trials for Focal Segmental Glomerulosclerosis (FSGS) and a second candidate DMX-700 in pre-clinical development for orphan respiratory/renal disease. The company leverages its proprietary Receptor-HIT cell-based assay platform to identify heteromer receptor interactions and discover differentiated drugs targeting GPCRs, and operates a global out-licensing model where regional pharmaceutical partners commercialize DMX-200 in their territories.

Is Dimerix Biosciences a public or private company?

Dimerix Biosciences is a public company. It is classified as public and is currently operating.

When was Dimerix Biosciences founded?

Dimerix Biosciences was founded in 2004. It employs 11 to 50 people.

Where is Dimerix Biosciences based?

Dimerix Biosciences is headquartered in Melbourne, Australia, in the Oceania region.

How does Dimerix Biosciences make money?

One revenue line is on record: licensing and milestone payments.

Who are Dimerix Biosciences's main competitors?

Direct peers on record are Travere Therapeutics, Chinook Therapeutics, Calliditas Therapeutics, ChemoCentryx and BridgeBio Pharma. Emerging players are Vera Therapeutics and Goldfinch Bio. Broad incumbents are Otsuka Pharmaceutical and Alexion / AstraZeneca Rare Disease. Amicus Therapeutics is listed as an others.

Does Dimerix Biosciences have an API?

No public API is recorded for Dimerix Biosciences.

What industry is Dimerix Biosciences in?

Dimerix Biosciences's product category is Clinical-Stage Biopharmaceuticals (Rare Kidney Disease). Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MorningstarDIMERIX SECURES A$34 MILLION NON-DILUTIVE FACILITY TO FUND KEY CLINICAL MILESTONESDimerix secured a non-dilutive loan facility of up to A$34 million from Australian and U.S. lenders, with 50% drawn down in September 2026. The funding supports the ACTION3 Phase 3 trial of DMX-200 and the Phase 2 trial of DMX-652 in acute kidney injury. The company has no plans to access the optional additional A$16 million.The AustralianDimerix banks US$10m upfront Everest paymentDimerix received a US$10 million upfront payment under a licensing agreement with Everest Medicines for its kidney drug candidate DMX-200, covering Greater China, South Korea and selected Southeast Asian countries. Everest holds exclusive rights and Dimerix is eligible for up to US$330 million in milestones plus 10-15% tiered royalties. Across five regional deals, Dimerix has secured over $80 million in upfront payments.Labiotech.euEight biotech companies in Melbourne you should know aboutAn article highlights eight biotech companies in Melbourne, detailing their therapeutic focuses, clinical trial progress, and recent financial or regulatory milestones. Key developments include Telix Pharmaceuticals' revenue growth and FDA approvals for its radiopharmaceuticals, Mesoblast's profitable launch of Ryoncil, and Dimerix licensing its kidney disease drug DMX-200 to Everest Medicines.YahooDimerix acquisition of DMX-652 bolsters kidney disease developmentDimerix, a clinical-stage biopharmaceutical company focused on kidney disease treatments, has acquired DMX-652 from Mission Therapeutics, adding a Phase II-ready acute kidney injury (AKI) programme. The acquired asset is an oral USP30 inhibitor designed to improve mitochondrial quality control, complementing Dimerix's existing late-stage FSGS asset DMX-200 and extending the company's development footprint across both acute and chronic kidney disease. AKI currently has no approved disease-modifying therapy, making this acquisition strategically significant for expanding Dimerix's relevance to nephrologists, hospitals, and trial networks.Pharmaceutical TechnologyDimerix acquisition of DMX-652 bolsters kidney disease development - Pharmaceutical TechnologyDimerix, a clinical-stage biopharmaceutical company focused on kidney disease treatments, has acquired DMX-652 from Mission Therapeutics, adding a Phase II-ready acute kidney injury programme with a differentiated USP30 inhibitor mechanism. The acquisition extends Dimerix's pipeline beyond its late-stage focal segmental glomerulosclerosis asset, creating a development continuum from acute injury to chronic kidney disease. The drug candidate already has supportive Phase I safety data and an open US investigational new drug application, reducing clinical execution risk.GlobalDataDimerix’s DMX-652 acquisition to bolster kidney disease therapy development, says GlobalData – GlobalDataDimerix acquired DMX-652 from Mission Therapeutics, adding a Phase II-ready acute kidney injury (AKI) program with a differentiated USP30 inhibitor mechanism to its kidney disease pipeline. The acquisition expands Dimerix beyond its existing late-stage focal segmental glomerulosclerosis asset, creating a development continuum from acute injury to chronic kidney disease that could increase relevance to nephrologists and hospital networks. DMX-652 has completed Phase I safety testing and holds open US IND/Phase II-ready status, with analysts noting AKI currently has no approved disease-modifying therapies, representing a high-unmet-need market.TradingViewDXB: Phase 3 FSGS trial fully recruited; DMX-652 phase 2 ready; global deals up to AU$1.9BDimerix Limited (DXB) has announced that its Phase 3 clinical trial of DMX-200 for Focal Segmental Glomerulosclerosis (FSGS) is fully recruited and statistically powered. The company also reported that DMX-652 has achieved Phase 2 readiness for Acute Kidney Injury (AKI), supported by strong safety data and a robust clinical plan. Dimerix has global licensing deals valued at up to AU$1.9 billion, with key milestones ahead including pivotal trial readouts and regulatory submissions.PharmaTimesMission Therapeutics divests MTX652 to Dimerix in deal worth up to $292 millionMission Therapeutics agreed to sell its phase 2-ready acute kidney injury candidate MTX652 to Dimerix for up to $292 million in upfront and milestone payments, plus royalties. The deal provides non-dilutive capital to accelerate Mission's lead CNS asset MTX325 for Parkinson's disease.PR Newswire APACDIMERIX EXPANDS PIPELINE WITH ACQUISITION OF PHASE 2 READY ASSET FOR ACUTE KIDNEY INJURYDimerix Limited announced the acquisition of DMX-652, a Phase 2-ready asset for acute kidney injury (AKI), from Mission Therapeutics Limited. The asset includes an open US IND with FDA-approved Phase 2 trial protocol targeting cardiac surgery-associated AKI, with strong Phase 1 safety data in 85 healthy volunteers and a global market opportunity estimated at US$3.5 billion in 2026. Financial terms include a US$5 million upfront payment, up to US$47 million in clinical development milestones, US$40 million on approval, US$25 million for a second indication, and up to US$175 million in sales milestones, plus 8-10% royalties on net sales.The AustralianDXB boosts drug pipeline and funding runwayDimerix (ASX:DXB) has secured a $10 million non-dilutive loan facility and acquired a Phase 2-ready acute kidney injury candidate (DMX-652) from Mission Therapeutics to expand its renal pipeline, with an upfront payment of $5 million plus development milestones and royalties. The funding, combined with existing cash reserves and an expected $14 million upfront payment from Everest Medicines, is specifically designated to complete the Phase 3 ACTION3 trial for DMX-200. The acquired asset includes a US IND application, FDA-approved Phase 2 clinical trial protocol, GMP drug product, and manufacturing methodology, with clinical trial ethics approval anticipated in H2 2026 and first patient dosing expected in H1 2027.